Business
Clene Reports Second Quarter 2021 Operating and Financial Highlights
Phase 2 REPAIR program demonstrated statistically significant improvements in brain energetic metabolism with CNM-Au8®, a gold nanocrystal suspension Phase 2,
About this update from Clene Inc.
[{"type":"text","content":"Phase 2 REPAIR program demonstrated statistically significant improvements in brain energetic metabolism with CNM-Au8®, a gold nanocrystal suspension Phase 2, placebo-controlled RESCUE-ALS trial remains on track for top-line data in 2H 2021 Interim blinded RESCUE-ALS efficacy data suggest CNM-Au8®, a gold nanocrystal suspension, may have neuro-reparative potential in people with amyotrophic lateral sclerosis Cash of $63 million as of June 30, 2021 SALT LAKE CITY, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today reported its second quarter 2021 operating and financial results. “Our recent progress has substantially bolstered our clinical data set and has us poised to achieve multiple milestones by the end of 2021, the most notable being the expected top-line data release from the placebo-controlled RESCUE-ALS trial,” said Rob Etherington, President and CEO of Clene. “Our Phase 2 REPAIR program in multiple sclerosis and Parkinson’s disease has shown that CNM-Au8 significantly improves energy metabolism in the brains of MS and PD patients. This is an exciting finding, as it clinically demonstrates CNM-Au8’s mechanism of action is broadly applicable and strongly supports the entirety of our clinical pipeline. We also presented highly encouraging blinded results from RESCUE-ALS last quarter, further adding to the robust set of clinical and preclinical data demonstrating CNM-Au8’s potential to become a breakthrough for patients with neurodegenerative disease.” Second Quarter 2021 and Recent Highlights CNM-Au8 for the treatment of multiple sclerosis (MS) and Parkinson’s disease (PD) Reported positive top-line results from the Phase 2 REPAIR clinical trialsThe objective of the REPAIR clinical trial program was to demonstrate the effects of Clene’s energy-enhancing nanotherapeutic, CNM-Au8, on brain energy metabolites in two sister studies of patients with Parkinson’s disease (REPAIR-PD) and multiple sclerosis (REPAIR-MS). Patients were imaged using 31phosphorous magnetic resonance spectroscopy, an innovative non-invasive brain imaging technique, before and after 12 weeks of daily or...